Pflugers Arch
Pflugers Archiv 
0031-6768
1432-2013
Springer-Verlag
Berlin/Heidelberg


2082651
17805561
326
10.1007/s00424-007-0326-z
Cardiovascular System


Criteria for arrhythmogenicity in genetically-modified Langendorff-perfused murine hearts modelling the congenital long QT syndrome type 3 and the Brugada syndrome

Sabir
Ian N.

1

Li
Lucia M.

1

Jones
Victoria J.

2

Goddard
Catharine A.

3

Grace
Andrew A.

3

Huang
Christopher L.-H.

+44-1223-333822
+44-1223-333840
clh11@cam.ac.uk

1
3

1
Physiological Laboratory, University of Cambridge, Downing Street, Cambridge, CB2 3EG UK 
2
Papworth Hospital, Papworth Everard, Cambridge, CB23 3RE UK 
3
Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QW UK 

6
9
2007

1
2008

455
4
637
651
30
6
2007

9
7
2007

10
7
2007


© Springer-Verlag 2007

Scn5a+/Δ
Scn5a+/−
Scn5a+/Δ
Scn5a+/−
P
 < 0.05) alterations in the DI at which slopes equalled unity, an established indicator of arrhythmogenicity, now successfully predicted the presence or absence of arrhythmogenicity in all cases. We thus associate changes in the slopes of restitution curves with arrhythmogenicity in models of LQT3 and BrS.

Keywords
Action potential
Arrhythmia
Heart
Heart rate
Heart excitation
Venticular muscle
Ventricle

issue-copyright-statement
© Springer-Verlag 2007




Introduction
SCN5a
+
gain-of-function
23
loss-of-function
1
2
].
31
33
22
24
7
39
38
12
30
].
2
3
42
20
46
3
13
27
42
3
2
29
21
33
38
39
42
].
14
17
19
28
40
11
25
43
44
11
26
32
45
] but has not been assessed in LQT3 or in BrS.
34
15
34
36
Scn5a+/Δ
13
Scn5a+/−
29
] before and after exposure to quinidine and flecainide. We proceed to demonstrate that while the former criterion fails, the latter produces predictions in full agreement with the arrhythmogenic findings in every case and thus suggest that alterations in the slopes of restitution curves are associated with arrhythmogenicity in both LQT3 and BrS.

Materials and methods
Experimental animals
Scn5a+/Δ
Scn5a+/−
 129 Sv mice aged 3–6 months were housed at 21 ± 1°C with 12 h light/dark cycles. They were fed sterile chow (RM3 Maintenance Diet, SDS, Witham, Essex, UK) and had free access to water. All procedures complied with the UK Animals (Scientific Procedures) Act 1986.

Solutions
3
2
4
2
2
2
2
9
].

Preparation
4
10
], at 2–2.5 ml/min, driven by a peristaltic pump (Watson-Marlow Bredel model 505S, Falmouth, Cornwall, UK). Hearts were regarded as suitable for experimentation if they regained a healthy pink colour and began to contract spontaneously on re-warming.

Electrophysiological measurements
8
]. The Teflon coating was removed from the distal 1 mm of the electrode; this was then galvanically chlorided to eliminate DC offset, inserted and placed against the septal endocardial surface. MAPs were amplified, band-pass filtered (0.5 Hz to 1 kHz: Gould 2400S, Gould-Nicolet Technologies, Ilford, Essex, UK) and digitised at a sampling frequency of 5 kHz (micro1401, Cambridge Electronic Design, Cambridge, UK). Analysis of MAPs was performed using Spike II (Cambridge Electronic Design, Cambridge, UK).

Experimental protocol
16
] and for at least 10 min. Before subsequent recordings were made, hearts were then exposed to test solutions for 20 min while stimulation was continued.
extrasystolic stimulation protocol
37
Scn5a+/Δ
Scn5a+/−
13
38
dynamic pacing protocol
17
] explained in detail below, and the data obtained used to construct restitution curves.

Data analysis
P
 ≤ 0.05). Curve fitting of particular functions to data sets used a Levenberg-Marquardt algorithm (OriginPro 7.5, OriginLab, MA, USA).


Results
Scn5a+/Δ
Scn5a+/−
6
] concentrations of flecainide (1 μM) and quinidine (1 or 10 μM). Hearts were exposed to solutions for 20 min while stimulated at a constant BCL of 125 ms before recording was commenced.
Scn5a+/Δ
Scn5a+/−
 hearts subject to both regular and extrasystolic stimulation recapitulates clinical observations
1
2
1
2
Scn5a+/Δ
1
2
Scn5a+/−
1
2
1
2
Fig. 1
a
Scn5a+/Δ
b
Scn5a+/−
c
A
B
C
D
). Traces show arrhythmic activity where this was observed in ≥50% of cases



Fig. 2
Scn5a+/Δ
Scn5a+/−
a
Scn5a+/Δ
b
Scn5a+/−
c
A
B
C
D
Hashing
dots
 indicate hearts not demonstrating such activity




2
Scn5a+/Δ
2
Scn5a+/−
2
c) exhibited arrhythmic activity during exposure to control solution (A). Such arrhythmic activity was also observed in one out of five hearts (~20%) treated with flecainide (B). Arrhythmic activity was then absent after treatment with either 1 μM (C) or 10 μM (D) quinidine (zero out of five, 0%, and zero out of six, 0%, hearts, respectively).
1
2
2
Scn5a+/Δ
2
Scn5a+/−
2
c, ii) demonstrated such arrhythmic activity in three out of nine cases (~33%) during treatment with control solution (A) but in five out of six cases (~83%) during treatment with flecainide (B). Furthermore, arrhythmic activity was observed in only one out of six such hearts (~17%) during treatment with 1 μM quinidine (C) and in zero out of six hearts during exposure to 10 μM quinidine (D).

Graphical analyses of arrhythmogenic tendency
90
17
90
90
90
17
25
28
43
].

Relationships between epicardial and endocardial action potential durations are not consistently associated with either the presence or absence of arrhythmogenicity
90
Scn5a+/Δ
42
Scn5a+/−
90
90
3
34
3
90
34
y
ax
2
bx
c
a
b
c
χ
2
y
mx
c
χ
2
F
N
\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$ F_{\chi }  = N{\left( {\frac{{\chi _{2} ^{2}  - \chi _{3} ^{2} }} {{\chi _{3} ^{2} }}} \right)} $$\end{document}

5
F
34
Fig. 3
90
a
Scn5a+/Δ
b
Scn5a+/−
c
A
B
C
D
Broken lines
y
ax
2
bx
c
 to data points obtained from wild-type hearts treated with control solution




3
34
]. However, data sets obtained before and after the pharmacological manoeuvres satisfied this expectation in WT but clearly failed to do so in the remaining genetically modified hearts.
3
in parallel with
2
Scn5a+/Δ
3
in contrast with
2
3
2
3
2
3
Scn5a+/−
3
2
3
2
3
2
c, C and D.

Alterations in the slopes of restitution curves correlate with the presence and absence of arrhythmic activity
90
4
5
4
5
Scn5a+/Δ
4
5
Scn5a+/−
4
5
90
Fig. 4
90
circles
a
Scn5a+/Δ
b
Scn5a+/−
c
A
B
C
D
90
solid lines
left ordinates
broken lines
right axes
Shaded boxes
 indicate ranges of DI values at which such gradients exceed unity



Fig. 5
90
squares
a
Scn5a+/Δ
b
Scn5a+/−
c
A
B
C
D
90
solid lines
left ordinates
broken lines
right axes
Shaded boxes
 indicate ranges of DI values at which such gradients exceed unity





Restitution curves yield parameters predictive of arrhythmogenicity
28
1
\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$y = y_{0}  + A{\left( {1 - e^{{{ - x} \mathord{\left/ {\vphantom {{ - x} \tau }} \right. \kern-\nulldelimiterspace} \tau }} } \right)}$$\end{document}

y
90
x
y
0

A
τ
90
χ
2
1
2
P
3
4
2
\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$ \frac{{dy}} {{dx}} = \frac{A} {\tau } \cdot e^{{ - x/\tau }}  $$\end{document}

Table 1
Fit parameters for epicardial restitution curves

Condition
y
0
 (ms)
A
 (ms)
τ
 (ms)
χ
2



WT (6 hearts)
1.6 ± 4.4
56.2 ± 2.4
58.4 ± 9.8
1.4

WT + flecainide (5 hearts)
−16.3 ± 9.4
104.7 ± 7.1
82.8 ± 28.0
5.9

WT + 1 μM quinidine (6 hearts)
−38.3 ± 17.4
92.4 ± 14.7
45.1 ± 9.4
2.5

WT + 10 μM quinidine (6 hearts)
−863.0 ± 1,387.1
981.6 ± 1,369.1
27.1 ± 15.9
113.3

Scn5a+/Δ
 (5 hearts)
−19.6 ± 7.2
90.0 ± 4.4
53.1 ± 10.7
14.0

Scn5a+/Δ
 + flecainide (5 hearts)
−16.1 ± 6.5
82.2 ± 12.3
95.3 ± 42.1
3.5

Scn5a+/Δ
 + 1 μM quinidine (5 hearts)
−677.1 ± 306.1
748.0 ± 304.7
15.2 ± 2.2
10.0

Scn5a+/−
 (6 hearts)
−674.8 ± 329.9
729.4 ± 329.1
14.2 ± 2.1
8.4

Scn5a+/−
 + flecainide (6 hearts)
−56,359.8 ± 2,559.7
52,677.3 ± 2.2
7.8 ± 2.5
14.8

Scn5a+/−
 + 1 μM quinidine (5 hearts)
−118.3 ± 57.4
202.5 ± 49.4
36.4 ± 10.5
16.7

Scn5a+/−
 + 10 μM quinidine (7 hearts)
−1.7 ± 44.7
131.9 ± 62.3
158.4 ± 262.2
10.8



\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$y = y_{0}  + A{\left( {1 - e^{{{ - x} \mathord{\left/ {\vphantom {{ - x} \tau }} \right. \kern-\nulldelimiterspace} \tau }} } \right)}$$\end{document}

 under the conditions indicated


Table 2
Fit parameters for endocardial restitution curves

Condition
y
0
 (ms)
A
 (ms)
τ
 (ms)
χ
2



WT (6 hearts)
−11.8 ± 3.7
73.8 ± 1.7
65.2 ± 8.4
1.2

WT + flecainide (5 hearts)
−769.0 ± 244.1
827.3 ± 243.7
14.5 ± 1.3
1.4

WT + 1 μM quinidine (6 hearts)
−65.8 ± 100.4
113.5 ± 98.3
24.9 ± 12.0
11.7

WT + 10 μM quinidine (6 hearts)
−41.9 ± 71.5
78.2 ± 68.7
32.8 ± 19.3
13.6

Scn5a+/Δ
 (5 hearts)
−31.9 ± 9.0
109.9 ± 5.1
49.6 ± 9.0
10.3

Scn5a+/Δ
 + flecainide (5 hearts)
−561.1 ± 1.2
631.6 ± 15.1
18.7 ± 0.3
6.7

Scn5a+/Δ
 + 1 μM quinidine (5 hearts)
−499.7 ± 143.8
563.0 ± 142.9
16.3 ± 1.6
56.0

Scn5a+/−
 (6 hearts)
−281.7 ± 9.8
43.5 ± 6.4
48.5 ± 19.0
4.3

Scn5a+/−
 + flecainide (6 hearts)
−1,050.6 ± 1,558.5
1,100.1 ± 1,557.8
11.7 ± 4.0
10.0

Scn5a+/−
 + 1 μM quinidine (5 hearts)
−261.2 ± 117.9
350.5 ± 107.8
34.2 ± 9.3
21.7

Scn5a+/−
 + 10 μM quinidine (7 hearts)
−220.1 ± 322.0
319.1 ± 316.8
26.2 ± 12.7
45.5



\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$y = y_{0}  + A{\left( {1 - e^{{{ - x} \mathord{\left/ {\vphantom {{ - x} \tau }} \right. \kern-\nulldelimiterspace} \tau }} } \right)}$$\end{document}

 under the conditions indicated


Table 3
Fit parameters for endocardial restitution curves separating successive odd- and even-numbered action potentials

Condition
Odd
Even

y
0
 (ms)
A
 (ms)
τ
 (ms)
χ
2

y
0
 (ms)
A
 (ms)
τ
 (ms)
χ
2



WT (6 hearts)
13.4 ± 7.6
40.5 ± 12.9
50.3 ± 21.4
6.3
8.1 ± 11.2
58.3 ± 25.4
48.2 ± 32.3
4.6

WT + flecainide (5 hearts)
−14.7 ± 8.9
105.2 ± 9.0
88.0 ± 31.3
5.8
−44.6 ± 18.5
117.4 ± 14.2
49.0 ± 9.9
1.5

WT + 1 μM quinidine (6 hearts)
−20.6 ± 9.9
75.8 ± 6.2
56.4 ± 13.2
3.8
−34.2 ± 11.7
89.2 ± 9.3
45.9 ± 7.8
3.3

WT + 10 μM quinidine (6 hearts)
−1,391.7 ± 3,195.9
1,496.0 ± 3,182.0
21.1 ± 14.3
117.9
−393.1 ± 5.3.0
532.8 ± 481.7
41.1 ± 27.6
115.7

Scn5a+/Δ
 (5 hearts)
−23.9 ± 8.3
92.0 ± 5.3
47.8 ± 9.0
12.4
−24.4 ± 8.6
92.6 ± 5.6
47.6 ± 8.9
11.8

Scn5a+/Δ
 + flecainide (5 hearts)
14.6 ± 6.3
77.1 ± 8.4
84.1 ± 32.2
3.4
−33.2 ± 46.4
110.1 ± 41.9
36.4 ± 13.1
2.0

Scn5a+/Δ
 + 1 μM quinidine (5 hearts)
−250.2 ± 12.8
483.0 ± 24.5
18.8 ± 7.8
12.4
−254.7 ± 321.2
328.1 ± 318.3
20.0 ± 7.7
5.3

Scn5a+/−
 (6 hearts)
−850.4 ± 282.7
904.2 ± 282.1
13.5 ± 1.3
4.3
−913.3 ± 283.3
968.6 ± 282.7
13.7 ± 1.2
3.7

Scn5a+/−
 + flecainide (6 hearts)
−1,473.8 ± 3,144.5
1,534.3 ± 2,141.2
14.7 ± 7.6
34.3
−2,108.8 ± 4,489.9
2,171.3 ± 4,486.8
14.0 ± 6.7
35.0

Scn5a+/−
 + 1 μM quinidine (5 hearts)
−46.8 ± 51.2
146.8 ± 21.3
59.5 ± 43.5
9.4
−46.7 ± 50.6
149.2 ± 20.2
61.0 ± 44.2
9.3

Scn5a+/−
 + 10 μM quinidine (7 hearts)
7.3 ± 34.2
167.7 ± 264.8
272.8 ± 78.3
10.8
2.8 ± 44.6
143.1 ± 121.3
192.2 ± 405.8
12.0



\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$y = y_{0}  + A{\left( {1 - e^{{{ - x} \mathord{\left/ {\vphantom {{ - x} \tau }} \right. \kern-\nulldelimiterspace} \tau }} } \right)}$$\end{document}

 under the conditions indicated


Table 4
Fit parameters for endocardial restitution curves separating successive odd- and even-numbered action potentials

Condition
Odd
Even

y
0
 (ms)
A
 (ms)
τ
 (ms)
χ
2

y
0
 (ms)
A
 (ms)
τ
 (ms)
χ
2



WT (6 hearts)
−17.4 ± 5.3
73.8 ± 2.8
67.3 ± 13.5
4.7
−38.9 ± 15.4
91.6 ± 13.0
46.5 ± 8.5
1.8

WT + flecainide (5 hearts)
−49.2 ± 26.2
113.8 ± 23.0
35.7 ± 8.2
7.6
−367.3 ± 171.3
426.9 ± 170.6
17.7 ± 2.4
1.3

WT + 1 μM quinidine (6 hearts)
−393.2 ± 368.6
437.7 ± 368.6
14.9 ± 4.3
18.1
−1,337.3 ± 1,206.4
1,384.5 ± 1,205.7
11.5 ± 2.5
14.7

WT + 10 μM quinidine (6 hearts)
−17.7 + −39.0
53.2 ± 35.0
42.6 ± 28.9
11.2
−28.0 ± 62.7
66.6 ± 58.2
39.6 ± 29.7
17.3

Scn5a+/Δ
 (5 hearts)
−149.6 ± 131.4
221.0 ± 128.6
26.4 ± 7.6
0.9
−42.3 ± 10.5
115.3 ± 8.2
40.8 ± 5.0
2.6

Scn5a+/Δ
 + flecainide (5 hearts)
−1,133.8 ± 784.2
1,201.4 ± 783.1
15.2 ± 2.6
2.0
−2,164.0 ± 1,195.7
2,233.3 ± 1,195.0
13.6 ± 1.6
1.4

Scn5a+/Δ
 + 1 μM quinidine (5 hearts)
−2,720.4 ± 3,917.8
2,779.7 ± 3,917.2
10.4 ± 2.8
3.4
−3,527.2 ± 4,674.78
3,603.0 ± 4,674.1
11.1 ± 2.7
3.9

Scn5a+/−
 (6 hearts)
−134.6 ± 28.9
195.3 ± 28.0
22.8 ± 2.1
3.3
−149.1 ± 33.5
212.0 ± 32.6
22.9 ± 2.2
3.6

Scn5a+/−
 + flecainide (6 hearts)
−13.8 ± 29.2
66.2 ± 27.1
32.5 ± 11.1
1.8
−55.4 ± 55.5
108.6 ± 54.6
23.6 ± 5.9
1.2

Scn5a+/−
 + 1 μM quinidine (5 hearts)
−1,979.9 ± 1,709.0
2,051.5 ± 1,704.6
15.9 ± 2.8
13.4
−108.4 ± 15,101.8
10,911.4 ± 15,098.3
11.8 ± 3.0
14.8

Scn5a+/−
 + 10 μM quinidine (7 hearts)
−332.1 ± 447.2
431.4 ± 439.8
25.2 ± 12.7
116.0
−160.0 ± 289.5
262.2 ± 281.9
20.1 ± 18.1
48.1



\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$y = y_{0}  + A{\left( {1 - e^{{{ - x} \mathord{\left/ {\vphantom {{ - x} \tau }} \right. \kern-\nulldelimiterspace} \tau }} } \right)}$$\end{document}

 under the conditions indicated



4
5
1
1
2
2
25
3
\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$ {\text{critical}} \,{\text{DI}} =  - \tau  \cdot \ln {\left( {\frac{\tau } {A}} \right)} $$\end{document}


6
A
τ
90
in complete agreement
Fig. 6
filled bars
open bars
4
5
a
Scn5a+/Δ
b
Scn5a+/−
c
A
B
C
D
Asterisks
P
 < 0.05) larger than those recorded in WT hearts exposed to control solution




6
P
5
2
6
P
2
6
P
2
paralleled
 with arrhythmogenicity in WT hearts treated with flecainide and quinidine.
Scn5a+/Δ
6
P
2
6
2
23
6
P
P
2
6
P
2
33
Scn5a+/Δ
 hearts treated with 10 μM quinidine.
Scn5a+/−
6
P
1
2
6
2
, ii).
Thus, while relationships between epicardial and endocardial action potential durations obtained over a range of cycle lengths are poorly correlated with arrhythmogenicity, restitution curves are, in general, predictive of arrhythmogenicity under the genetic and pharmacological conditions studied.


Discussion
3
SCN5a
+
1
23
].
Scn5a+/Δ
13
Scn5a+/−
29
39
38
] models. Epicardial and endocardial MAP recordings were then used to evaluate the applicability of two established criteria in predicting arrhythmogenicity in these models over the full physiological range of heart rates (quantified as baseline cycle lengths, BCLs).
90
34
at a single
Scn5a+/Δ
42
90
34
34
Scn5a+/Δ
Scn5a+/−
Scn5a+/Δ
all
Scn5a+/−
on
increased
failed
pro
did
anti
-arrhythmic effect.
90
14
17
19
28
40
45
any
any
32
any
 species.
Scn5a+/Δ
Scn5a+/−
Scn5a+/Δ
Scn5a+/−
Scn5a+/Δ
Scn5a+/−
32
] in the critical DI: Such changes are in full agreement with effects on arrhythmogenicity in all cases.
Scn5a
+
28
40
41
].


Acknowledgements
We thank the James Baird Fund, the Frank Elmore Fund, the Medical Research Council, the Wellcome Trust, the British Heart Foundation and Downing College, Cambridge for their generous support. Ian N. Sabir and Lucia M. Li have contributed equally to this work.

References
1.
Antzelevitch
C

Brugada
P

Brugada
J

Brugada
R

Towbin
JA

Nademanee
K


Brugada syndrome: 1992–2002: A historical perspective
J Am Coll Cardiol
2003
41
1665
1671
10.1016/S0735-1097(03)00310-3

12767644


2.
Antzelevitch C, Burashnikov A, Di Diego JM (2003) Cellular and ionic mechanisms underlying arrhythmogenesis. In: Cardiac repolarization: bridging basic and clinical science. Humana Press, Totowa, N.J

3.
Antzelevitch
C

Yan
GX

Shimizu
W


Transmural dispersion of repolarization and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome
J Electrocardiol
1999
32
Suppl
158
165
10.1016/S0022-0736(99)90074-2

10688320


4.
Balasubramaniam
R

Grace
AA

Saumarez
RC

Vandenberg
JI

Huang
CL


Electrogram prolongation and nifedipine-suppressible ventricular arrhythmias in mice following targeted disruption of KCNE1
J Physiol
2003
552
535
546
10.1113/jphysiol.2003.048249

14561835


5.
Bevington
PR


Data reduction and error analysis for the physical sciences
1969
New York
McGraw-Hill

Bevington PR (1969) Data reduction and error analysis for the physical sciences. McGraw-Hill, New York 

6.
Birkett
DJ


Therapeutic drug monitoring
Aust Prescr
1997
20
9
11

Birkett DJ (1997) Therapeutic drug monitoring. Aust Prescr 20:9–11 

7.
Brugada
R


Use of intravenous antiarrhythmics to identify concealed Brugada syndrome
Curr Control Trials Cardiovasc Med
2000
1
1
45
47
10.1186/CVM-1-1-045

11714408


8.
Casimiro
MC

Knollmann
BC

Ebert
SN

Vary
JC

Greene
AE

Franz
MR

Grinberg
A

Huang
SP

Pfeifer
K


Targeted disruption of the Kcnq1 gene produces a mouse model of Jervell and Lange-Nielsen Syndrome
Proc Natl Acad Sci USA
2001
98
2526
2531
10.1073/pnas.041398998

11226272


9.
Farkas
A

Curtis
MJ


Limited antifibrillatory effectiveness of clinically relevant concentrations of class I antiarrhythmics in isolated perfused rat hearts
J Cardiovasc Pharmacol
2002
39
412
424
10.1097/00005344-200203000-00013

11862121


10.
Fernandez del Pozo
B

Perez-Vizcaino
F

Fernandez
C

Zaragoza
F

Tamargo
J


Effects of several class I antiarrhythmic drugs on isolated rat aortic vascular smooth muscle
Gen Pharmacol
1997
29
539
543
10.1016/S0306-3623(96)00517-4

9352299


11.
Garfinkel
A

Kim
YH

Voroshilovsky
O

Qu
Z

Kil
JR

Lee
MH

Karagueuzian
HS

Weiss
JN

Chen
PS


Preventing ventricular fibrillation by flattening cardiac restitution
Proc Natl Acad Sci USA
2000
97
6061
6066
10.1073/pnas.090492697

10811880


12.
Grace
AA

Camm
AJ


Quinidine
N Engl J Med
1998
338
35
45
10.1056/NEJM199801013380107

9414330


13.
Head
CE

Balasubramaniam
R

Thomas
G

Goddard
CA

Lei
M

Colledge
WH

Grace
AA

Huang
CL


Paced electrogram fractionation analysis of arrhythmogenic tendency in DeltaKPQ Scn5a mice
J Cardiovasc Electrophysiol
2005
16
1329
1340

16403066


14.
Karagueuzian
HS

Khan
SS

Hong
K

Kobayashi
Y

Denton
T

Mandel
WJ

Diamond
GA


Action potential alternans and irregular dynamics in quinidine-intoxicated ventricular muscle cells. Implications for ventricular proarrhythmia
Circulation
1993
87
1661
1672

8491022


15.
Killeen
M

Thomas
G

Gurung
I

Goddard
C

Fraser
J

Mahaut-Smith
M

Colledge
H

Grace
A

Huang
C


Arrhythmogenic mechanisms in the isolated perfused hypokalemic murine heart
Acta Physiol
2007
189
33
46
10.1111/j.1748-1716.2006.01643.x

Killeen M, Thomas G, Gurung I, Goddard C, Fraser J, Mahaut-Smith M, Colledge H, Grace A, Huang C (2007) Arrhythmogenic mechanisms in the isolated perfused hypokalemic murine heart. Acta Physiol 189:33–46 

16.
Knollmann
BC

Katchman
AN

Franz
MR


Monophasic action potential recordings from intact mouse heart: validation, regional heterogeneity, and relation to refractoriness
J Cardiovasc Electrophysiol
2001
12
1286
1294
10.1046/j.1540-8167.2001.01286.x

11761418


17.
Koller
ML

Riccio
ML

Gilmour
RF


Dynamic restitution of action potential duration during electrical alternans and ventricular fibrillation
Am J Physiol
1998
275
H1635
H1642

9815071


18.
Koller
ML

Riccio
ML

Gilmour
RF


+
o
 on electrical restitution and activation dynamics during ventricular fibrillation
Am J Physiol Heart Circ Physiol
2000
279
H2665
H2672

11087219


19.
Lee
JJ

Kamjoo
K

Hough
D

Hwang
C

Fan
W

Fishbein
MC

Bonometti
C

Ikeda
T

Karagueuzian
HS

Chen
PS


Reentrant wave fronts in Wiggers’ stage II ventricular fibrillation. Characteristics and mechanisms of termination and spontaneous regeneration
Circ Res
1996
78
660
675

8635224


20.
Lukas
A

Antzelevitch
C


Phase 2 reentry as a mechanism of initiation of circus movement reentry in canine epicardium exposed to simulated ischemia
Cardiovasc Res
1996
32
593
603
10.1016/0008-6363(96)00115-0

8881520


21.
Milberg
P

Reinsch
N

Wasmer
K

Monnig
G

Stypmann
J

Osada
N

Breithardt
G

Haverkamp
W

Eckardt
L


Transmural dispersion of repolarization as a key factor of arrhythmogenicity in a novel intact heart model of LQT3
Cardiovasc Res
2005
65
397
404
10.1016/j.cardiores.2004.10.016

15639478


22.
Moss A, Windle J, Hall W, Zareba W, Robinson J, McNitt S, Severski P, Rosero S, Daubert J, Qi M, Cieciorka M, Manalan A (2005) Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (KPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Annals of Non-invasive Electrocardiology 10(suppl):59–66

23.
Moss
AJ

Kass
RS


Long QT syndrome: from channels to cardiac arrhythmias
J Clin Invest
2005
115
2018
2024
10.1172/JCI25537

16075042


24.
Napolitano
C

Priori
S


Brugada Syndrome
Orphanet J Rare Dis
2006
1
35
40
10.1186/1750-1172-1-35

16972995


25.
Nolasco
JB

Dahlen
RW


A graphic method for the study of alternation in cardiac action potentials
J Appl Physiol
1968
25
191
196

5666097


26.
Omichi
C

Zhou
S

Lee
MH

Naik
A

Chang
CM

Garfinkel
A

Weiss
JN

Lin
SF

Karagueuzian
HS

Chen
PS


Effects of amiodarone on wave front dynamics during ventricular fibrillation in isolated swine right ventricle
Am J Physiol Heart Circ Physiol
2002
282
H1063
H1070

11834505


27.
Opthof
T

Coronel
R


Transmural dispersion in LQT3 and arrhythmogenesis
Cardiovasc Res
2005
68
336
337
10.1016/j.cardiores.2005.07.006

16054611


28.
Pak
HN

Hong
SJ

Hwang
GS

Lee
HS

Park
SW

Ahn
JC

Moo Ro
Y

Kim
YH


Spatial dispersion of action potential duration restitution kinetics is associated with induction of ventricular tachycardia/fibrillation in humans
J Cardiovasc Electrophysiol
2004
15
1357
1363
10.1046/j.1540-8167.2004.03569.x

15610278


29.
Papadatos
GA

Wallerstein
PM

Head
CE

Ratcliff
R

Brady
PA

Benndorf
K

Saumarez
RC

Trezise
AE

Huang
CL

Vandenberg
JI

Colledge
WH

Grace
AA


Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a
Proc Natl Acad Sci USA
2002
99
6210
6215
10.1073/pnas.082121299

11972032


30.
Pratt
CM

Moye
LA


The cardiac arrhythmia suppression trial. Casting suppression in a different light
Circulation
1995
91
245
247

7805210


31.
Priori
SG

Napolitano
C

Schwartz
PJ

Bloise
R

Crotti
L

Ronchetti
E


The elusive link between LQT3 and Brugada syndrome: The role of flecainide challenge
Circulation
2000
102
945
947

10961955


32.
Riccio
ML

Koller
ML

Gilmour
RF


Electrical restitution and spatiotemporal organization during ventricular fibrillation
Circ Res
1999
84
955
963

10222343


33.
Roden
D

Anderson
M


Proarrhythmia
Handb Exp Pharmacol
2006
171
73
97

16610341


34.
Sabir IN, Fraser JA, Cass TR, Grace AA, Huang CL (2007a) A quantitative analysis of the effect of cycle length on arrhythmogenicity in hypokalaemic Langendorff-perfused murine hearts. Pflugers Arch PMID: 17437126

35.
Sabir
IN

Fraser
JA

Killeen
MJ

Grace
AA

Huang
CL


The contribution of refractoriness to arrhythmic substrate in hypokalaemic Langendorff-perfused murine hearts
Pflugers Arch
2007
454
209
222
10.1007/s00424-007-0217-3

17295037


36.
Sabir
IN

Killeen
MJ

Goddard
CA

Thomas
G

Gray
S

Grace
AA

Huang
CL


Transient alterations in transmural repolarization gradients following premature ventricular depolarizations in arrhythmogenic hypokalaemic Langendorff-perfused murine hearts
J Physiol
2007
581
277
289
10.1113/jphysiol.2007.128637

17331992


37.
Saumarez
RC

Grace
AA


Paced ventricular electrogram fractionation and sudden death in hypertrophic cardiomyopathy and other non-coronary heart diseases
Cardiovasc Res
2000
47
11
22
10.1016/S0008-6363(00)00096-1

10869526


38.
Stokoe
KS

Balasubramaniam
R

Goddard
CA

Colledge
WH

Grace
AA

Huang
CL


Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/− murine hearts
J Physiol
2007
578
69
84
10.1113/jphysiol.2006.117945

17023504


39.
Stokoe
KS

Thomas
G

Goddard
CA

Colledge
WH

Grace
AA

Huang
CL


Scn5a
+/Δ murine hearts modelling long QT syndrome 3
J Physiol
2007
578
69
84
10.1113/jphysiol.2006.117945

17023504


40.
Taggart
P

Sutton
P

Chalabi
Z

Boyett
MR

Simon
R

Elliott
D

Gill
JS


Effect of adrenergic stimulation on action potential duration restitution in humans
Circulation
2003
107
285
289
10.1161/01.CIR.0000044941.13346.74

12538429


41.
Tan
HL

Hofman
N

Langen
IM

Wal
AC

Wilde
AA


Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives
Circulation
2005
112
207
213
10.1161/CIRCULATIONAHA.104.522581

15998675


42.
Thomas G, Gurung IS, Killeen MJ, Hakim P, Goddard CA, Mahaut-Smith MP, Colledge WH, Grace AA, Huang CL (2007a) Effects of L-type Ca2+ channel antagonism on ventricular arrhythmogenesis in murine hearts containing a modification in the Scn5a gene modelling human long QT syndrome 3. J Physiol 578:85–97

43.
Weiss
JN

Chen
PS

Qu
Z

Karagueuzian
HS

Garfinkel
A


Ventricular fibrillation: how do we stop the waves from breaking?
Circ Res
2000
87
1103
1107

11110766


44.
Weiss
JN

Karma
A

Shiferaw
Y

Chen
PS

Garfinkel
A

Qu
Z


From pulsus to pulseless: the saga of cardiac alternans
Circ Res
2006
98
1244
1253
10.1161/01.RES.0000224540.97431.f0

16728670


45.
Yamauchi
S

Yamaki
M

Watanabe
T

Yuuki
K

Kubota
I

Tomoike
H


Restitution properties and occurrence of ventricular arrhythmia in LQT2 type of long QT syndrome
J Cardiovasc Electrophysiol
2002
13
910
914
10.1046/j.1540-8167.2002.00910.x

12380931


46.
Yan
G-X

Antzelevitch
C


Cellular Basis for the Brugada Syndrome and Other Mechanisms of Arrhythmogenesis Associated With ST-Segment Elevation
Circulation
1999
100
1660
1666

10517739





